The present invention relates to compounds of formula (I):
wherein R
1
to R
3
, A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing them, and methods for treating CNS disorders.
The present invention relates to compounds of formula (I):
wherein R
1
to R
3
, A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing them, and methods for treating CNS disorders.
Compounds as metabotropic glutamate receptor antagonists
申请人:Hoffmann-La Roche Inc.
公开号:US07504404B2
公开(公告)日:2009-03-17
The present invention relates to compounds of formula (I)
wherein A, E G, J, L, M, R1, R2, and R3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment of a variety of CNS disorders.
SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS
申请人:Gatti McArthur Silvia
公开号:US20120041002A1
公开(公告)日:2012-02-16
The present invention relates to compounds of formula (I)
wherein A, E G, J, L, M, R
1
, R
2
, and R
3
are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment of a variety of CNS disorders.
Substituted pyrazolo [1,5-A] pyrimidines as metabotropic glutamate antagonists
申请人:Hoffmann-La Roche Inc.
公开号:US08349844B2
公开(公告)日:2013-01-08
The present invention relates to compounds of formula (I)
wherein A, E G, J, L, M, R1, R2, and R3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment of a variety of CNS disorders.